Randomized Clinical Trial to Evaluate Safety, Tolerability and PK-PD Profile of Metformin Glycinate 620 mg,1240 mg, 2480 mg and Metformin Chlorhydrate 1000 mg of One Single Dose, Multiple Dose and After Food Intake.
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 49
- Locations
- 2
- Primary Endpoint
- Step A: Number of Adverse Events of Metformin Glycinate 620 mg QD, 1240 mg QD, 2480 mg QD, after administration of one single dose
Study Overview
Brief Summary
Metformin Glycinate is a novel biguanide compound developed as a potential candidate for the treatment of type 2 diabetes. Metformin Glycinate was found to improve metabolic control in naive patients with type 2 diabetes.
The objective of this study is to evaluate the safety, tolerability and pK profile of Metformin Glycinate 620 mg QD, 1240 mg QD, 2480 mg QD, after administration of one single dose, in step A. In step A will be included 25 volunteers.
In step B the objective is to evaluate Safety, tolerability and pK profile of Metformin Glycinate 620 mg BID, after administration of multiple dose during 8 days. In step B will be included 24 volunteers.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age between 18 and 45 years.
- •Weight within normal ranges (Quetelet index between 21 and 26) (weight (kg)/height (m2).
- •Adequate physical examination and clinical history
- •No organic and psychiatric disorder
- •Normal Blood pressure, Pulse Rate, temperature and ECG.
- •Lab test within normal values according to reference lab values of Biochemistry lab of Hospital Santa Creu I Sant Pau. It will be allowed changes according to clinical criteria of the clinical staff of ICIM-SANT PAU
- •Females of childbearing potential with adequate contraceptive precautions, other than oral contraceptives and negative urine pregnancy test.
- •No participation in any other clinical trial within the previous two months before the initiation of this study.
- •No blood donation within the previous four weeks before the initiation of this study.
- •Signed informed consent.
Exclusion Criteria
- •Drugs or alcohol abuse.
- •Consumer of stimulant drinks (> 5 coffees, teas, cola drinks).
- •Smokers (> 10 cigars).
- •Precedents of drugs allergy or hypersensitivity
- •Intake of any other medication within the previous 15 days before this study.
- •Positive HIV, HBV or HCV.
- •Chronic disease (cardiovascular, respiratory, endocrine, gastrointestinal, hematologic, neurologic or others).
- •Prior surgery within the previous six months before the initiation of this study.
- •Pregnant women or breastfeeding or females of childbearing potential with no adequate contraceptive precautions, other than oral contraceptives.
Arms & Interventions
Step A: metformin glycinate 620 mg
620mg single dose by mouth
Intervention: Step A: metformin glycinate 620 mg single dose (Drug)
Step A: metformin glycinate 1240 mg
1240mg single dose by mouth
Intervention: Step A: metformin glycinate 1240 mg single dose (Drug)
Step A: metformin glycinate 2480 mg
2480mg single dose by mouth
Intervention: Step A: metformin glycinate 2480 mg single dose (Drug)
Step A: metformin hydrochloride 1000 mg
1000mg single dose by mouth
Intervention: Step A: metformin hydrochloride 1000 mg single dose (Drug)
Step A: metformin glycinate 1240 mg, food intake
1240mg single dose by mouth after food intake
Intervention: Step A: metformin glycinate 1240 mg,food intake (Drug)
Step B: metformin glycinate 620 mg BID
620mg BID for 8 days
Intervention: Step B: metformin glycinate 620 mg BID (Drug)
Step B: metformin hydrochloride 500 mg BID
500mg tablets BID for 8 days
Intervention: Step B: metformin hydrochloride 500 mg BID (Drug)
Outcomes
Primary Outcomes
Step A: Number of Adverse Events of Metformin Glycinate 620 mg QD, 1240 mg QD, 2480 mg QD, after administration of one single dose
Time Frame: 35 days
Tolerability: * adverse events, * systolic and diastolic blood pressure, pulse rate and temperature * pulse rate and ECG alterations * alterations in haematology, plasma chemistry, and urine analyses
Step B: Number of Adverse Events of Metformin Glycinate 620 mg BID, after administration of multiple dose during 8 days
Time Frame: 25 days
Tolerability: * adverse events, * systolic and diastolic blood pressure, pulse rate and temperature * pulse rate and ECG alterations * alterations in haematology, plasma chemistry, and urine analyses
Secondary Outcomes
- Step A: Bioavailability (Cmax) of metformin glycinate 1240 mg QD in fasted subjects and after the intake of fat rich breakfast(36 hours)
- Step A: Bioavailability (AUC) of metformin glycinate 1240 mg QD in fasted subjects and after the intake of fat rich breakfast(36 hours)
- Step A: Bioavailability (AUC) of metformin glycinate 620 mg QD, 1240 mg QD, 2480 mg QD after administration of one single dose with metformin Chlorhydrate 1000 mg QD.(36 hours)
- Step A: Linear and dose-proportional (AUC) pharmacokinetic of 620 mg, 1240 mg and 2480 strengths of metformin glycinate(36 hours)
- Step A: Pharmacokinetic profile (AUC) of metformin glycinate 620mg QD, 1240 mg QD, 2480 mg QD after administration one single dose and pharmacokinetic profile of metformin chlorhydrate 1000mg QD.(36 hours)
- Step B: Bioavailability (AUC) of metformin glycinate 620 mg BID and bioavailability of metformin chlorhydrate 500mg BID, after administration of multiple doses during 8 days.(8 days)
- Step A: Pharmacokinetic profile (Cmax) of metformin glycinate 620mg QD, 1240 mg QD, 2480 mg QD after administration one single dose and pharmacokinetic profile of metformin chlorhydrate 1000mg QD.(36 hours)
- Step B: Bioavailability (Cmax) of metformin glycinate 620 mg BID and bioavailability of metformin chlorhydrate 500mg BID, after administration of multiple doses during 8 days.(8 days)
- Step B: Pharmacokinetic profile (Cmax) of metformin glycinate 620mg BID after administration of multiple doses during 8 days(8 days)
- Step B: Pharmacokinetic profile (AUC) of metformin glycinate 620mg BID after administration of multiple doses during 8 days(8 days)
- Step A: Bioavailability (Cmax) of metformin glycinate 620 mg QD, 1240 mg QD, 2480 mg QD after administration of one single dose with metformin Chlorhydrate 1000 mg QD.(36 hours)
- Step A: Linear and dose-proportional pharmacokinetic (Cmax) of 620 mg, 1240 mg and 2480 strengths of metformin glycinate(36 hours)